Author | Hayley Virgil

Articles

Limited Activity Shown With Durvalumab/Tremelimumab in Advanced NETs Subtypes

September 22, 2020

Results from the DUNE trial of durvalumab added to tremelimumab in patients with advanced neuroendocrine tumors of gastroenteropancreatic and lung origins showed limited activity, according to a presentation held during the 2020 European Society of Medical Oncology Virtual Congress.

Nivolumab Plus Chemotherapy Extends PFS With Durable Responses in Gastric/GEJ Cancers

September 21, 2020

In the phase 3 ATTRACTION-4 study, nivolumab added to chemotherapy led to a statistically significant improvement in progression-free survival and induced higher overall response rates in patients with previously untreated advanced or recurrent gastric and gastroesophageal junction cancer, according to results presented during the 2020 ESMO Virtual Congress.

Phase 3 Trial Results Do Not Support PORT in Resected Stage IIIAN2 NSCLC

September 20, 2020

Patients with completely resected stage IIIAN2 non–small cell lung cancer should not be recommended for post-operative radiotherapy, according to results from the phase 3 LungART trial that were presented during the ESMO Virtual Congress 2020, due to nonstatistically significant increase in disease-free survival versus those treated in the control group.

Abemaciclib Doublet Demonstrates OS Benefit in HR+, HER2- Metastatic Breast Cancer

September 20, 2020

Abemaciclib in combination with tamoxifen led to an improvement in overall survival compared with abemaciclib alone in patients with hormone receptor–positive, HER2-negative metastatic breast cancer. Notably, the benefit of the combination was observed across all subgroups in the study, according to findings from the final OS analysis of the nextMONARCH trial presented during the 2020 European Society of Medical Oncology Virtual Congress.